Sign in
CompletedPhase 1/2

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

Key facts

Who runs it
BioNTech SE
Where
Charlottesville, Chesterfield, Hialeah, Honolulu, Houston, Lake Forest, Las Vegas, Mesquite, Miami, Miami Lakes, Milford, Omaha, Orlando, Portsmouth, Salt Lake City, San Diego, Springfield, Stockbridge, Tomball, and Walnut Creek, United StatesSee the 22 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
1,353 people enrolled
Started
11 Nov 2024
Ended
15 Jul 2025
Type of study
Interventional, 15 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Investigational Influenza Vaccine
  • COVID-19 Vaccine
  • Investigational Influenza/COVID-19 Vaccine
  • Licensed Influenza Vaccine 1
  • Licensed Influenza Vaccine 2
  • Placebo
Record updated
19 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants 18 years of age or older
  • Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study

Who cannot take part

  • Treated with antiviral therapies for influenza (eg, Tamiflu) within 180 days prior to Day 1; Please refer to the study contact for further eligibility details
  • Vaccination with any investigational or licensed 2024-2025 season formulation influenza or COVID-19 vaccine

Where in United States

  • Charlottesville Medical ResearchCharlottesville, United States
  • Clinical Research ProfessionalsChesterfield, United States
  • Indago Research & Health Center, IncHialeah, United States
  • East-West Medical Research InstituteHonolulu, United States
  • DM Clinical Research- CyfairHouston, United States
  • Orange County Research CenterLake Forest, United States
  • Las Vegas Clinical TrialsLas Vegas, United States
  • SMS Clinical ResearchMesquite, United States
  • Miami Dade Medical Research Institute, LLCMiami, United States
  • Palm Springs Community Health CenterMiami Lakes, United States
  • Clinical Research ConsultingMilford, United States
  • Velocity Clinical Research - OmahaOmaha, United States
  • Headlands Research OrlandoOrlando, United States
  • ActivMed Practices & Research, LLC.Portsmouth, United States
  • J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic SouthSalt Lake City, United States
  • Artemis Institute for Clinical ResearchSan Diego, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MOSpringfield, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment CenterSpringfield, United States
  • Clinical Research AtlantaStockbridge, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical ResearchTomball, United States
  • Diablo Clinical Research, Inc.Walnut Creek, United States

About the trial

What the trial wants to find out

This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.

The 15 groups in the trial

  • Arm A/AATreatment being tested

    Low Dose COVID-19 Vaccine and Placebo

    Treatment: COVID-19 Vaccine and Placebo

  • Arm B/BBTreatment being tested

    Medium Dose COVID-19 Vaccine and Placebo

    Treatment: COVID-19 Vaccine and Placebo

  • Arm C/CCExisting treatment, for comparison

    High Dose COVID-19 Vaccine and Placebo

    Treatment: COVID-19 Vaccine and Placebo

  • Arm D/DDTreatment being tested

    Low Dose Investigational Influenza Vaccine and Placebo

    Treatment: Investigational Influenza Vaccine and Placebo

  • Arm EExisting treatment, for comparison

    Licensed Influenza Vaccine 1 and Licensed COVID-19 Vaccine

    Treatment: COVID-19 Vaccine and Licensed Influenza Vaccine 1

  • Arm EEExisting treatment, for comparison

    Licensed Influenza Vaccine 2 and Licensed COVID-19 Vaccine

    Treatment: COVID-19 Vaccine and Licensed Influenza Vaccine 2

  • Arm F/FFTreatment being tested

    Medium Dose Investigational Influenza Vaccine and Placebo

    Treatment: Investigational Influenza Vaccine and Placebo

  • Arm G/GGTreatment being tested

    Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

  • Arm H/HHTreatment being tested

    Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

  • Arm I/IITreatment being tested

    Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

  • Arm J/JJTreatment being tested

    High Dose Investigational Influenza Vaccine and Placebo

    Treatment: Investigational Influenza Vaccine and Placebo

  • Arm K/KKTreatment being tested

    Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

  • Arm L/LLTreatment being tested

    Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

  • Arm M/MMTreatment being tested

    High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

  • Arm NTreatment being tested

    High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo

    Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS
Record updated
19 August 2026